Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (ACRS) is a publicly traded company in the Unknown sector. Across all available filings, 36 corporate insiders have executed 514 transactions totaling $159.0M, demonstrating a bearish sentiment with -$29.7M in net insider flow. The most recent transaction on Feb 3, 2026 involved a transaction of 18,675 shares valued at $0.
ACRS Insider Activity Summary
Who Is Buying ACRS Stock?
No significant insider buying has been recorded for ACRS in the recent period.
Who Is Selling ACRS Stock?
No significant insider selling has been recorded for ACRS in the recent period.
Is Aclaris Therapeutics, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for ACRS is bearish with an Insider Alignment Score of 41/100 and a net flow of -$29.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
ACRS Frequently Asked Questions
Understanding ACRS Insider Activity
Insider trading at Aclaris Therapeutics, Inc. (ACRS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 36 insiders are actively trading ACRS stock, having executed 514 transactions in the past 90 days. The most active insider is Anand Mehra (Executive), who has made 11 transactions totaling $30.0M.
Related Tools
Track Aclaris Therapeutics, Inc. Insider Activity
Get notified when executives and directors at ACRS file new Form 4 transactions